Children with HIV in Africa - Pharmacokinetics and Adherence of Simple Antiretroviral Regimens (CHAPAS-2)
| ISRCTN | ISRCTN01946535 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN01946535 |
| Protocol serial number | N/A |
| Sponsor | Medical Research Council (UK) |
| Funder | Monument Trust (UK) (ref: grant ID - MON4951) |
- Submission date
- 28/02/2011
- Registration date
- 28/04/2011
- Last edited
- 28/04/2011
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Plain English summary of protocol
Not provided at time of registration
Contact information
Scientific
Medical Research Council
Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Open randomised controlled phase I crossover trial |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Children with HIV in Africa - Pharmacokinetics and Adherence of Simple Antiretroviral Regimens (CHAPAS-2): an open, randomised, controlled, phase I, crossover trial |
| Study acronym | CHAPAS-2 |
| Study objectives | 1. There is no difference in blood drug levels (overall area under the plasma concentration time curve (AUC) and Cmin) among children aged 4-13 years taking Cipla sprinkle or Cipla tablet formulations of ritonavir-boosted-lopinavir together with food and also compared to historical controls. 2. There is no difference in blood drug levels (overall area under the plasma concentration time curve (AUC) and Cmin) among infants (under 1 year) taking Abbott Kaletra® syrup or Cipla sprinkle formulations of ritonavir-boosted-lopinavir together with food according to World Health Oragnisation (WHO) doses and weightbands and also compared to historical controls. |
| Ethics approval(s) | 1. UCL Research Ethics Committee approved on 19th October 2009, (ref: application 1665/001) 2. Joint Clinical Research Centre IRB approved on 30th October 2009 3. Ugandan National Council of Science and Technology approved on 23rd April 2010 |
| Health condition(s) or problem(s) studied | Human immunodeficiency virus (HIV) |
| Intervention | 24 children (aged 4-13 years able to take paediatric LPV/r tablets and either currently receiving LPV/r or about to start LPV/r containing ART) in a (1:1) ratio to LPV/r either in sprinkle or tablet formulation with food. After 4 weeks on allocated treatment children will have a 12 hour pharmacokinetcis (PK) day with 7 blood draws (1.5-2.5ml each). Children will then switch LPV/r formulation to the other formulation (sprinkle or tablet) and continue to take that formulation with food for a further 4 weeks. At week 8, children will have a second 12 hour PK day of 7 blood draws (1.5-2.5ml each) after which children will choose which formulation of LPV/r they wish to remain on. A third non-randomised intervention arm will include infants from 3 months to 1 year, already receiving or about to start LPV/r syrup with food. Infants will be followed for 4 weeks followed by a 12 hour PK day. They will then switch formulation to receive LPV/r sprinkle with food for 4 weeks followed by a second 12 hour PK day of 7 blood draws (1.5-2.5ml each) at week 8. |
| Intervention type | Other |
| Primary outcome measure(s) |
1. To determine the pharmacokinetics (PK) of ritonavir-boosted-lopinavir (LPV/r) in a twice daily paediatric co-formulated fixed dose sprinkle combination (Lopimune, Cipla pharmaceuticals) and compare it to LPV/r in a twice daily paediatric co-formulated fixed dose tablet combination (Cipla Pharmaceuticals), both with food, in HIV-infected African children aged 4-12 years |
| Key secondary outcome measure(s) |
1. To compare the formulation preferences of children and their carers in terms of sprinkle or tablets |
| Completion date | 01/03/2012 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Neonate |
| Sex | All |
| Target sample size at registration | 40 |
| Key inclusion criteria | 1. Human immunodeficiency virus (HIV) infected infants aged 3 months to < 12 months currently taking or about to start Lopinavir/ritonavir (LPV/r) syrup based first-line following WHO guidelines 2008 [7] or 2. HIV infected children able to swallow paediatric LPV/r tablets and aged 4-13 years and < 25Kg, currently taking or about to start LPV/r based second-line following WHO guidelines 2. Carers and children where appropriate, willing and able to give informed consent |
| Key exclusion criteria | Children: 1. Who are expected to change weight bands (i.e. change dose) after enrollment and before PK day at week 8 2. With anaemia (haemoglobin < 8.5g/dL) or liver enzymes grade 2 or higher 3. With illnesses that could influence the pharmacokinetics of the antiretroviral (ARV) drugs at week 4 and week 8 e.g. severe diarrhoea, vomiting, renal or liver disease 4. On concomitant medications that are known to interact with the ARV drugs |
| Date of first enrolment | 15/04/2011 |
| Date of final enrolment | 01/03/2012 |
Locations
Countries of recruitment
- United Kingdom
- England
- Uganda
Study participating centre
NW1 2DA
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
